Survival of patients with node-negative lung cancer and chest wall invasion
Authors:
- Anupama SinghASAnupama Singh
- Ashley L. DeebADAshley L. Deeb
- Camille Mathey-AndrewsCMCamille Mathey-Andrews
- Miles McAllisterMMMiles McAllister
- Alexandra L. PotterAPAlexandra L. Potter
- Emanuele MazzolaEMEmanuele Mazzola
- Yue XieYXYue Xie
- Chi-Fu Jeffrey YangCYChi-Fu Jeffrey Yang
- Paula Ugalde FigueroaPFPaula Ugalde Figueroa
Open Access
- 1 September 2025
- journal article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (9) , 6451-6460
Abstract
Background: Patients with T3 non-small cell lung cancer (NSCLC) with chest wall invasion (CWI) have poorer survival than patients with T3 NSCLC defined by other T3 descriptors, but their survival has not been compared with patients with T4 NSCLC. Our objective was to compare the survival of patients with NSCLC with CWI, currently a T3 descriptor, with that of patients with T4 NSCLC. Methods: A retrospective analysis was conducted of the National Cancer Database (NCDB) comparing patients diagnosed with node-negative NSCLC Results: In total, 1,734 matched patients were studied (867 T3 with CWI, 867 T4). There were no significant differences in baseline demographics, tumor characteristics, treatment, or surgical approach used (all P>0.05). There were no significant differences in 30-day (P=0.27) or 90-day (P=0.33) mortality between the two groups. Five-year OS was also similar between the two groups [44.0% T3 with CWI, 95% confidence interval (CI): 41–47% vs. 43.8% T4, 95% CI: 40–47%; P=0.50]. Median survival was 40 months (range 0.2–123 months for the T3 cohort and 0.3–120 months for the T4 cohort). Conclusions: CWI might serve better as a T4 descriptor in future iterations of the Tumor, Node, Metastasis (TNM) classifications. This would allow providers to better stage and treat patients, which would subsequently affect survival.Keywords
This publication has 13 references indexed in Scilit:
- Factors Associated with Nodal Upstaging in Clinical T1a-bN0M0 Non-Small Cell Lung CancersCancers, 2022
- Primary lung cancer with chest wall involvementLung India, 2021
- Exploring the Potential Different Outcomes Associated With the Different Phenotypes Under the Shared Pathologic T3N0 DesignationJTO Clinical and Research Reports, 2021
- A Population-Based Study of Outcomes in Surgically Resected T3N0 Non–Small Cell Lung Cancer in The Netherlands, Defined Using TNM-7 and TNM-8; Justification of Changes and an Argument to Incorporate Histology in the Staging AlgorithmJournal of Thoracic Oncology, 2019
- Chest wall/parietal pleural invasions worsen prognosis in T4 non-small cell lung cancer patients after resectionGeneral Thoracic and Cardiovascular Surgery, 2019
- Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non–small cell lung cancer invading the chest wallThe Journal of Thoracic and Cardiovascular Surgery, 2018
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2016
- Pathologic Upstaging in Patients Undergoing Resection for Stage I Non-Small Cell Lung Cancer: Are There Modifiable Predictors?The Annals of Thoracic Surgery, 2015
- The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2015
- Chest wall invasion in non–small cell lung carcinoma: A rationale for en bloc resectionThe Journal of Thoracic and Cardiovascular Surgery, 2001